RyboDyn, Inc., a biotech company pioneering first-in-class immunotherapies targeting the dark proteome, has been selected to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc.
RyboDyn gets direct access to Eli Lilly and Company’s global scientific and business network—a critical catalyst as it advances its lead programmes.
RyboDyn discovered a cryptic proteome—a previously uncharacterised layer of protein-coding potential derived from overlooked RNA species. Through its sequencing and AI-driven platform, RyboCypher, the company has uncovered a new class of therapeutic targets that are cancer-specific, abundantly expressed on the cell surface, and absent in healthy tissues. In collaboration with Moffitt Cancer Center, RyboDyn recently demonstrated that several ‘Dark Targets’ are conserved across patients, supporting their potential as the foundation for first-in-class precision immunotherapies.
“We’re thrilled to join the LGL community and collaborate with peers who share our urgency to translate high-impact science,” said Imad Ajjawi, CEO and co-founder of RyboDyn.
“Lilly’s support comes at a pivotal moment as we advance our first wave of programs toward therapeutic development.”
RyboDyn’s LGL residency is part of the Lilly Catalyze360 model to empower early-stage biotech startups across all therapeutic areas by providing access to lab space and drug development talent and resources through its three pillars: Lilly Gateway Labs, Lilly ExploR&D, and Lilly Ventures.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
